Boomfish Wealth Group’s Esperion Therapeutics ESPR Stock Holding History

Boomfish Wealth Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-45,306	Closed	-$143K	–	104
2026 Q2	$143K	Hold	45,306	–	–	0.07%	94
2026 Q1	$124K	Hold	45,306	–	–	0.07%	86
2025 Q4	$168K	Hold	45,306	–	–	0.09%	85
2025 Q3	$120K	Hold	45,306	–	–	0.06%	87
2025 Q2	$44.6K	Buy	45,306 +10,309	+29%	+$10.3K	0.03%	87
2025 Q1	$50.4K	Hold	34,997	–	–	0.03%	82
2024 Q4	$77K	Hold	34,997	–	–	0.05%	93
2024 Q3	$57.7K	Buy	34,997 +5,102	+17%	+$10.3K	0.04%	89
2024 Q2	$66.4K	Hold	29,895	–	–	0.04%	86
2024 Q1	$80.1K	Buy	+29,895	New	+$72.6K	0.05%	87

Other funds holding ESPR

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Boomfish Wealth Group's ESPR Position: Q3 2026 in Review

Boomfish Wealth Group sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 45,306 shares — an estimated $143K sold.

Boomfish Wealth Group first reported a position in ESPR in Q1 2024 and held it in 10 quarters. The position peaked at $168K in Q4 2025. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

Boomfish Wealth Group reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
Boomfish Wealth Group sold 45,306 Esperion Therapeutics shares in Q3 2026, an estimated $143K.
Boomfish Wealth Group first reported a position in Esperion Therapeutics in Q1 2024 and held it in 10 quarters.
Boomfish Wealth Group's Esperion Therapeutics position peaked at $168K in Q4 2025.
2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Boomfish Wealth Group's 13F filing for Q3 2026, filed 22 Oct 2026.